| P50 | author | Michele Simonato | Q62108855 |
| | Stefano Cattaneo | Q92155674 |
| P2093 | author name string | Silvia Zucchini | |
| | Gianluca Verlengia | |
| | Selene Ingusci | |
| P2860 | cites work | Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease | Q58730756 |
| | Transduction Patterns of Pseudotyped Lentiviral Vectors in the Nervous System | Q61970603 |
| | Exosome-associated AAV vector as a robust and convenient neuroscience tool | Q88677614 |
| | Biochemical autoregulatory gene therapy for focal epilepsy | Q89486311 |
| | A MicroRNA-Based Gene-Targeting Tool for Virally Labeling Interneurons in the Rodent Cortex | Q89568541 |
| | Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue | Q24523651 |
| | A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells | Q28249434 |
| | A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner | Q28256353 |
| | AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 |
| | Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model | Q30487459 |
| | Neuropeptide Y: emerging evidence for a functional role in seizure modulation. | Q33544242 |
| | Engineered HSV vector achieves safe long-term transgene expression in the central nervous system | Q33685490 |
| | Chemical-genetic attenuation of focal neocortical seizures | Q33729364 |
| | Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates | Q33731243 |
| | Safety and tolerability of putaminal AADC gene therapy for Parkinson disease | Q33731687 |
| | A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease | Q34209755 |
| | Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein | Q34214473 |
| | Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy | Q34311339 |
| | AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method | Q34330377 |
| | Gene therapy for epilepsy. | Q34375803 |
| | Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. | Q34397099 |
| | Gene therapy in epilepsy-is it time for clinical trials? | Q34410588 |
| | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 |
| | Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 |
| | Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. | Q35111738 |
| | Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. | Q35280041 |
| | The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. | Q35341751 |
| | Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity | Q35542643 |
| | Differential Effect of Neuropeptides on Excitatory Synaptic Transmission in Human Epileptic Hippocampus. | Q35680811 |
| | Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy | Q35799349 |
| | Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. | Q35853990 |
| | Regulatable gene expression systems for gene therapy applications: progress and future challenges | Q36157542 |
| | Design and development of polymers for gene delivery | Q36211579 |
| | Transduction of brain by herpes simplex virus vectors | Q36681937 |
| | Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector | Q36951265 |
| | Transport and egress of herpes simplex virus in neurons | Q36997308 |
| | The challenge and promise of anti-epileptic therapy development in animal models | Q37214420 |
| | Nonviral vectors for gene delivery | Q37340494 |
| | Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors | Q37445505 |
| | Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins. | Q37643999 |
| | Progress in gene therapy for neurological disorders. | Q38100997 |
| | Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease | Q38839079 |
| | A largely random AAV integration profile after LPLD gene therapy | Q39401822 |
| | Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors | Q40238020 |
| | Adeno-associated viral vector-mediated preprosomatostatin expression suppresses induced seizures in kindled rats | Q40347390 |
| | Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS | Q41647072 |
| | Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types | Q41841879 |
| | HIV-1-based lentiviral vectors | Q42259821 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 |
| | Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. | Q42944984 |
| | Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery | Q43685007 |
| | Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system | Q45007196 |
| | Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein | Q45399638 |
| | Structural analysis of adeno-associated virus transduction circular intermediates. | Q45747262 |
| | Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector | Q45769447 |
| | Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. | Q45872925 |
| | Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy | Q45873849 |
| | Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison | Q45880308 |
| | Triple Vectors Expand AAV Transfer Capacity in the Retina | Q47559127 |
| | Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. | Q48380900 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 38-43 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Epilepsy Currents | Q5382972 |
| P1476 | title | A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy | |
| P478 | volume | 19 | |